Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of intravitreal conbercept in neovascular age-related macular degeneration (nAMD)
ChiCTR2300072734Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of conbercept in exudative macular degeneration (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Best corrected visual acuity (BCVA). Started Jun 2023; status: completed.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2300072734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072734.